Velpatasvir is a NS5A inhibitor used to treat chronic hepatitis C infections in patients without cirrhosis or with compensated cirrhosis. Velpatasvir is a Direct-Acting Antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
- Mechanism
- Curator reviewed · 2 references
Velpatasvir's mechanism of action is likely similar to other selective NS5A inhibitors which bind domain I of NS5A consisting of amino acids 33-202. NS5A inhibitors compete with RNA for binding at this site. It is also thought that NS5A inhibitors bind the target during its action in replication when the binding site is exposed. Inhibition of NS5A is also known to produce redistribution of the protein to lipid droplets. The exact role of NS5A in RNA replication is not yet understood although it is known to be an important component.
- Primary indication
- Velpatasvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients.Curator reviewed · 6 structured indications
- Formula / weight
- C49H54N8O8 · 883.019 g/mol (avg)
- First approval
- Canada, 2016 · United States, 2016 · European Union, 2016
- Code names
- GS-5816
- Brand names
Resolves to
FHCUMDQMBHQXKK-CDIODLITSA-NSMILESCOC[C@H]1C[C@H](N(C1)C(=O)[C@H](NC(=O)OC)C1=CC=CC=C1)C1=NC=C(N1)C1=CC=C2C(COC3=CC4=C(C=CC5=C4NC(=N5)[C@@H]4CC[C@H](C)N4C(=O)[C@@H](NC(=O)OC)C(C)C)C=C23)=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Velpatasvir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account